

Curing & Preventing Cancer

A holistic, long-term approach

CONCEPT PAPER · JUNE 2026

◆ The premise

Cancer is not a problem that yields to a single discovery, a single company, or a single funding cycle. It is a generational problem — biologically tangled, slow to surrender, and indifferent to the calendars of the people trying to solve it. Most of the money aimed at it is structured for the opposite: short horizons, defined exits, returns measured in a handful of years rather than the decades the problem actually asks for. The result is a field that is brilliant in its parts and incoherent as a whole — remarkable science pursued inside structures that cannot afford to wait for it.

BioFund exists to remove that contradiction. It began not with a business plan but with a sentence. In 2018, a scientist said, plainly, “*I will cure cancer.*” The reasonable response to that sentence is skepticism. The honest response is to ask what it would actually take — and then to build the thing that makes the work possible and protects it from everything that usually kills it: impatience, the need to sell, the pressure to narrow a mission down to whatever can be exited fastest.

What follows is the shape of that answer. It is deliberately high-level: the frame, not the blueprint.

◆ What “holistic” means here

Holistic is an easy word to abuse, so it is worth being precise about what it means in this context. It does not mean doing everything. It means refusing three separations that conventional approaches treat as natural, and that we believe are the reason the conventional approaches stall.

We do not separate prevention from cure. Almost all of oncology is organized around treating people who are already sick. That work is essential and we are deeply in it. But the largest gains against cancer over a lifetime come earlier — from reducing the burden the body carries before disease takes hold. Prevention is unglamorous, slow to prove, and

nearly impossible to fund in a normal model because no one exits a healthy population. That is precisely why it belongs to us. An evergreen structure can hold prevention work long enough for it to matter.

We do not separate species. Cancer is not a uniquely human affliction. Dogs and other companion animals develop cancers spontaneously, with biology that often resembles our own far more faithfully than an engineered mouse ever will. Treating their disease is not a detour on the way to human medicine. It is care for those animals in its own right, and at the same time it is a faster, more honest, more predictive path to therapies that will one day reach people.

We do not separate capital from mission. In the standard arrangement, money and purpose are in tension — the investor's clock works against the scientist's. BioFund is built so the two pull in the same direction. The capital is structured to want what the mission wants: time.

These three refusals are the whole idea. Everything else is how we act on them.

◆ **OneHealth: one biology, many species**

OneHealth is the methodological spine of the work. The conviction underneath it is simple: cancer is largely one problem wearing different coats. Tumour biology, the failures of the immune system, the mechanisms that let cells escape their own controls — these are conserved across mammals. If that is true, then the wall we have built between veterinary and human oncology is mostly an accident of how the industries grew up, not a fact of nature.

So we start with companion animals. Their cancers arise naturally, in animals that live in our homes, breathe our air, and age on a timescale we can actually observe. A therapy validated in a dog with a real, spontaneous tumour tells us something a forced rodent model cannot. And the animals themselves are patients, not instruments — they are treated to be helped.

This sequence — companion animals first, then humans — is faster, more ethical, and more predictive than the path the field defaults to. It is also where the science and the conscience of the project happen to agree, which is usually a sign that an approach is sound.

◆ Two engines

A mission this long needs durable machinery underneath it – not a string of products, but platforms that keep producing. BioFund runs on two.

The first engine makes the medicine. It is a cell-engineering platform: the capability to design, build, and produce the biological tools that modern oncology depends on – engineered cell lines, biologic proteins and their biosimilars, and therapeutics aimed first at companion-animal cancers. This was built for our own research and is opened, selectively, to partners whose work shares the mission. It is the supply side of the cure.

The second engine makes prevention real. It is the UFP500 platform – a way of processing natural compounds into ultra-fine particles so that the body can actually absorb and use them. Bioactive compounds are abundant in nature and largely wasted in practice, because most of what we eat passes through us before it can do any good. UFP500 attacks that loss directly, raising the bioavailability of the compounds that matter. It expresses itself through RAFFINÉ in the culinary world and through PURE in functional wellness, and it lets us build targeted prevention – for example, nutrition designed for firefighters and others with heavy, repeated exposure to carcinogenic combustion. This is the supply side of prevention.

One engine works on the disease. The other works on the conditions that precede it. Together they cover the whole arc – which is the point.

◆ The flywheel

A mission that depends on perpetual generosity is fragile. Generosity tires; circumstances change; the work outlives the goodwill that started it. So the economics are designed to sustain themselves.

Mission capital funds the platforms. The platforms give rise to commercial activities – culinary and wellness brands built on UFP500, the licensing of biological tools, companion-animal therapeutics – and those activities license the platforms back and generate revenue. That revenue refuels the mission. Over time, the cure and prevention work is meant to be carried less and less by fresh capital and more and more by the value the platforms themselves create.

This is the flywheel: mission funds platforms, platforms spin out commerce, commerce refuels the mission. It is what allows a non-exit organization to keep going without quietly becoming a charity case – and it is what lets us hold prevention and long-horizon science that no fund could justify.

◆ Built for the time the problem takes

None of this works without the right structure, and the structure is the part that is hardest to copy.

BioFund is backed by seven families and built to be evergreen and anti-exit. There is no liquidation event on the horizon distorting every decision behind it, no clock counting down to a forced sale. That single design choice changes what becomes possible. It lets us pursue prevention, which has no exit. It lets us run OneHealth properly, in the right sequence, rather than rushing to whatever can be monetized first. It lets us build platforms as decade-long assets rather than props for the next round.

This is what we mean by legacy — not a word on a wall, but a structural fact. The organization is meant to outlast its founders and to be judged on a timescale that matches the disease, not the market.

◆ No one can do it alone

The mission is too large for any single group, and we have never pretended otherwise. The work runs through partnerships — in animal health, in academic oncology, in the circular bioeconomy that supplies and sustains the prevention platform. We bring capital that can wait, platforms that produce, and a structure that lets collaborators do their best work without being absorbed or rushed. What we ask in return is alignment of purpose.

◆ The pillars, briefly

The way BioFund works can be read off seven commitments that run through everything above: **private capital** that answers to the mission rather than a market; **speed** where the science allows it and **agility** where the path changes; **compassion** as the reason for the work and the standard for how the animals and people in it are treated; **innovation** in the platforms that make the rest possible; **prevention** as an equal partner to cure; and **legacy** built into the structure so the work survives the people who started it.

◆ In closing

The approach can be stated in a sentence. We treat cancer as one problem across species, work both ends of it — prevention and cure — and have built the kind of organization that can stay in the fight for as long as the fight takes.

That last part is the quiet difference. Most of the field is structurally unable to wait. We are built to. The science will be hard enough on its own; we have removed at least the self-inflicted obstacles — the exit pressure, the artificial walls, the false choice between doing good and lasting.

*Curing and preventing cancer together.
Because no one can do it alone.*

BIOFUND